Alligator Bioscience Publishes Clinical Phase I Data for ADC-1013 in the International Journal of Cancer

LUND, Sweden, Jan. 29, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), announces the publication of the results from a clinical phase I first-in-human study of the CD40 agonistic antibody ADC-1013 (JNJ-64457107). The top line data from this study was presented at the...

from PR Newswire: https://prn.to/2TljFea